Elucidation of Potential Genotoxicity of MXenes Using a DNA Comet Assay
Sergiy Kyrylenko, Inna Chorna, Zhanna Klishchova, Ilya Yanko, Anton Roshchupkin, Volodymyr Deineka, Kateryna Diedkova, Anastasia Konieva, Oksana Petrichenko, Irina Kube-Golovin, Gunther Wennemuth, Emerson Coy, Iryna Roslyk, Ivan Baginskiy, Veronika Zahorodna, Oleksiy Gogotsi, Benjamin Chacon, Luciana P. Cartarozzi, Alexandre L. R. Oliveira, Igor Iatsunskyi, Yury Gogotsi, and Maksym Pogorielov. Elucidation of Potential Genotoxicity of MXenes Using a DNA Comet Assay. ACS Applied Bio Materials 2024 7 (12), 8351-8366. DOI: 10.1021/acsabm.4c01142
MXenes are among the most diverse and prominent 2D materials. They are being explored in almost every field of science and technology, including biomedicine. In particular, they are being investigated for photothermal therapy, drug delivery, medical imaging, biosensing, tissue engineering, blood dialysis, and antibacterial coatings. Despite their proven biocompatibility and low cytotoxicity, their genotoxicity has not been addressed. To investigate whether MXenes interfere with DNA integrity in cultured cells, we loaded the cells with MXenes and examined the fragmentation of their chromosomal DNA by a DNA comet assay.
The presence of both Ti3C2Tx and Nb4C3Tx MXenes generated DNA comets, suggesting a strong genotoxic effect in murine melanoma and human fibroblast cells. However, no corresponding cytotoxicity was observed, confirming that MXenes were well tolerated by the cells. The lateral size of the MXene flakes was critical for developing the DNA comets; submicrometer flakes induced the DNA comets, while larger flakes did not. MXenes did not induce DNA comets in dead cells. Moreover, the extraction of the chromosomal DNA from the MXene-loaded cells or mixing the purified DNA with MXenes showed no signs of DNA fragmentation. Unconstrained living MXene-loaded cells did not show cleavage of the DNA with MXenes under electrophoresis conditions. Thus, the DNA comet assay showed the ability of submicrometer MXene particles to penetrate living cells and induce DNA fragmentation under the applied field.
The most probable mechanism of DNA comet formation is the rotation and movement of submicrometer MXene flakes inside cells in an electric field, leading to cleavage and DNA shredding by MXene’s razor-sharp edges. Under all other conditions of interest, titanium- and niobium-carbide-based MXenes showed excellent biocompatibility and no signs of cytotoxicity or genotoxicity. These findings may contribute to the development of strategies for cancer therapy.
KEYWORDS: Ti3C2Tx, Nb4C3Tx, MXene, DNA comet assay, DNA fragmentation, cell viability, resazurin reduction assay, cell death, electrophoresis
Reference: ACS Appl. Bio Mater. 2024, 7, 12, 8351–8366 https://doi.org/10.1021/acsabm.4c01142
HORIZON Europe MX-MAP project #101086184: Towards MXenes’ biomedical applications by high-dimensional immune MAPping
Funded by the Marie Skłodowska-Curie Actions programme, the MX-MAP project will develop key strategies for MXene medical applications. The long-term goal of MX-MAP is to create a pipeline using new MXene nanomaterials for the qualitative and quantitative assessment of immunological compatibility in biomedical applications.
MXenes potential applications include sensors, wound healing materials, and drug delivery systems. A recent study explored how different synthesis methods affect the safety and performance of MXenes. By comparing etching conditions and intercalation strategies, researchers discovered that fine-tuning the surface chemistry of MXenes plays a crucial role in improving biocompatibility. These results provide practical guidelines for developing safer MXenes and bring the field one step closer to real biomedical applications.
Exellent news, our joint patent application with Drexel University on highly porous MAX phase precursor for MXene synthesis published. Congratulations and thanks to all team involved!
Last Call! Have you submitted your abstract for IEEE NAP-2025 yet? Join us at the International Symposium on "The MXene Frontier: Transformative Nanomaterials Shaping the Future" – the largest MXene-focused conference in Europe this year! Final Submission Deadline: May 15, 2025. Don’t miss this exclusive opportunity to showcase your research and engage with world leaders in the MXene field!
We are excited to announce the publication of latest review article on MXenes in Healthcare. This comprehensive review explores the groundbreaking role of MXenes—an emerging class of 2D materials—in revolutionizing the fields of medical diagnostics and therapeutics. Read the full article here: https://doi.org/10.1039/D4NR04853A.
Congratulations and thank you to our collaborators from TU Wien and CEST for very interesting work and making it published! In this work, an upscalable electrochemical MXene synthesis is presented. Yields of up to 60% electrochemical MXene (EC-MXene) with no byproducts from a single exfoliation cycle are achieved.
Thank you to our collaborators for the amazing joint work recently published in Graphene and 2D Nanomaterials about MXene–silk fibroin composite films aiming to develop materials with tunable electronic and thermal properties
Dr. Oleksiy Gogotsi, director of MRC and Carbon-Ukraine, innovative companies that are among the leaders on the world MXene market, visited 2024 MRS Fall Meeting & Exhibit. together with Dr. Maksym Pogorielov, Head of Advanced Biomaterials and Biophysics Laboratory, University of Latvia.
MRC and Carbon-Ukraine team visited the 3rd International MXene conference held at Drexel University on August 5-8, 2024. Conference brought together the best reserchers and leading experts on MXene field. 
Together with colleagues from the University of Latvia, MRC/Carbone Ukraine, Adam Mickiewicz University, University Clinic Essen, and others, we have developed a novel concept involving the binding of antibodies to MXenes. In our research, we utilized anti-CEACAM1 antibodies to develop targeted photo-thermal therapy for melanoma (in vitro), paving the way for future in vivo studies and clinical trials. For the first time, we demonstrate the feasibility of delivering MXenes specifically targeted to melanoma cells, enabling the effective ablation of cancer cells under near-infrared (NIR) light. This new technique opens up vast potential for the application of MXenes in cancer treatment, diagnostics, drug delivery, and many other medical purposes.
